Literature DB >> 2133086

Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene.

F P Guengerich1.   

Abstract

A series of 17 alpha-acetylenic steroids was examined with regard to ability to inactivate human liver microsomal cytochrome P-450 (P-450) IIA4, an enzyme involved in the oxidation of a number of drugs, carcinogens, and steroids, including estrogens and progestogens. Of the eight compounds tested, gestodene was found to be particularly active as a mechanism-based inactivator of P-450 IIIA4. Inhibition of both microsomal nifedipine oxidation and 17 alpha-ethynylestradiol (EE) 2-hydroxylation was dependent upon NADPH and gestodene concentration. Rates of inactivation were pseudo first order-values of kinactivation = 0.4 min-1 and Ki = 46 microM and a partition ratio of 9 were calculated. The kinactivation is approximately 50-fold greater than estimated for EE and is one of the highest reported for P-450 mechanism-based inactivators. Spectrally detectable P-450 was also destroyed in microsomes, but several experiments indicate that little covalent binding to amino acid residues of P-450 IIIA4 occurs. Microsomal inactivation of P-450 could be blocked by the presence of other P-450 IIIA4 substrates, and several activities catalyzed by other P-450s were not inhibited under conditions in which greater than 90% of P-450 IIIA4 was inactivated. Consideration of structure/activity relationships among the 17 alpha-acetylenic steroids examined indicates that the delta 15 double bond is critical but is not in itself sufficient for the inactivation process, which is postulated to result from attack of P-450 on the substituted acetylenic carbon and lead to porphyrin N-alkylation. The effectiveness of this mechanism-based inactivator may account for reports of increased estrogen and steroid levels in some women using gestodene in oral contraceptives.

Entities:  

Keywords:  Americas; Biology; Clinical Research; Contraception; Contraceptive Agents, Estrogen--pharmacodynamics; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods--pharmacodynamics; Developed Countries; Diseases; Drug Interactions; Drugs; Embolism; Enzyme Inhibitors; Enzymes And Enzyme Inhibitors; Ethinyl Estradiol--pharmacodynamics; Examinations And Diagnoses; Family Planning; Gestodene--pharmacodynamics; Hepatic Effects; In Vitro; Laboratory Examinations And Diagnoses; Laboratory Procedures; Methodological Studies; North America; Northern America; Oral Contraceptives, Combined--pharmacodynamics; Oral Contraceptives--pharmacodynamics; Physiology; Research Methodology; Tennessee; Thromboembolism; Thrombosis; Treatment; United States; Vascular Diseases

Mesh:

Substances:

Year:  1990        PMID: 2133086     DOI: 10.1021/tx00016a015

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  42 in total

1.  The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Authors:  Donna J Belle; John T Callaghan; J Christopher Gorski; Juan F Maya; Omiema Mousa; Steven A Wrighton; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.

Authors:  S Palovaara; K T Kivistö; P Tapanainen; P Manninen; P J Neuvonen; K Laine
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

3.  Oxidation of dihydrotestosterone by human cytochromes P450 19A1 and 3A4.

Authors:  Qian Cheng; Christal D Sohl; Francis K Yoshimoto; F Peter Guengerich
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

Review 4.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 5.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Lack of interaction between meloxicam and warfarin in healthy volunteers.

Authors:  D Türck; C A Su; G Heinzel; U Busch; E Bluhmki; J Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

7.  Formation of pyridinium species of haloperidol in human liver and brain.

Authors:  D W Eyles; J J McGrath; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

Review 8.  Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.

Authors:  Victoria Tittle; Lauren Bull; Marta Boffito; Nneka Nwokolo
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 9.  Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.

Authors:  F Peter Guengerich; Francis K Yoshimoto
Journal:  Chem Rev       Date:  2018-06-22       Impact factor: 60.622

10.  Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.

Authors:  Julia Winkler; Mark Goldammer; Matthias Ludwig; Beate Rohde; Christian Zurth
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-06       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.